Biophytis GAAP EPS of -€9.48

Seeking AlphaOct 11 23:31

6-K: Report of foreign private issuer (related to financial reporting)

SECJun 27 01:48 · Announcements

H.C. Wainwright Maintains BIOPHYTIS SPON ADR EACH REP 4000 ORD(POST SPLIT)(BPTSY.US) With Buy Rating, Maintains Target Price $15

H.C. Wainwright analyst Joseph Pantginis maintains $BIOPHYTIS SPON ADR EACH REP 4000 ORD(POST SPLIT)(BPTSY.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the

Futu NewsJun 21 00:32 · Ratings

Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments

BenzingaJun 20 16:58

Biophytis Announces The Design Of Its Phase 2 OBA Clinical Study In Obesity With BIO101 (20-hydroxyecdysone)

BenzingaMay 14 15:36

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

BenzingaApr 26 01:57